Drug Trial Radar · NCT05412030
A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants
Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
388
Actual
Start
Jun 16, 2022
Primary completion
Sep 18, 2025
Study completion Sep 18, 2025
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Jun 9, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 42 days, up to 90 days
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 2 clinical study evaluating AFX3772 in healthy infants for the prevention of pneumococcal disease. The purpose of this study is to determine the safety, tolerability, and immunogenicity of three different formulations of AFX3772 compared with Prevnar 13 (PCV13) and Prevnar 20 (PCV20). Part 1 is the dose-escalation lead-in portion of the study, in which infants at each dose level are randomized 3:1 in sequential cohorts to receive increasing doses of AFX3772 or PCV13. In Part 2, infants are randomized to receive either one of two dose levels of AFX3772 or PCV20. On 31 October 2024, the study was placed on partial clinical hold by the U.S. Food and Drug Administration. The hold was not related to safety concerns in participants who had already received the study vaccines. As a result, enrollment was paused and no further doses of the investigational pneumococcal vaccine were administered. Participants who were already enrolled transitioned to the standard of care pneumococcal vaccine to complete their scheduled visits through post-dose 3 and subsequently completed study follow-up.
Conditions
- Pneumonia, Bacterial
- Pneumococcal Infections
- Pneumonia, Pneumococcal
Interventions
AFX3772Biological
AFX3772 administered intramuscularly.
Prevnar 13Biological
PCV13 administered intramuscularly.
Prevnar 20Biological
PCV 20 administered intramuscularly.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Reporting Any Solicited Injection Site Adverse Events (AEs) After First DoseTime frame: Day 1 to Day 7 post dose 1
- Number of Participants Reporting Any Solicited Injection Site AEs After Second DoseTime frame: Day 1 to Day 7 post dose 2
- Number of Participants Reporting Any Solicited Injection Site AEs After Third DoseTime frame: Day 1 to Day 7 post dose 3
- Number of Participants Reporting Any Solicited Systemic Events After First DoseTime frame: Day 1 to Day 7 post dose 1
- Number of Participants Reporting Any Solicited Systemic Events After Second DoseTime frame: Day 1 to Day 7 post dose 2
- Number of Participants Reporting Any Solicited Systemic Events After Third DoseTime frame: Day 1 to Day 7 post dose 3
- Number of Participants Reporting Any Unsolicited AEsTime frame: Within 30 days post each dose (at 2, 4, and 6 months of age as part of primary vaccination series)
- Number of Participants Reporting Any Serious Adverse Events (SAEs)Time frame: Day 1 through 6 months post dose 3
Locations
52 sites in 2 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Jonesboro, Arkansas
GSK Investigational Site
Gardena, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Madera, California
GSK Investigational Site
Ontario, California
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Pensacola, Florida
GSK Investigational Site
Saint Augustine, Florida
GSK Investigational Site
Tampa, Florida
GSK Investigational Site
Tampa, Florida
GSK Investigational Site
Nampa, Idaho
GSK Investigational Site
Bardstown, Kentucky
GSK Investigational Site
Lexington, Kentucky
GSK Investigational Site
Louisville, Kentucky
GSK Investigational Site
Covington, Louisiana
GSK Investigational Site
Haughton, Louisiana
GSK Investigational Site
Lafayette, Louisiana
GSK Investigational Site
New Orleans, Louisiana
GSK Investigational Site
Mankato, Minnesota
GSK Investigational Site
Missoula, Montana
GSK Investigational Site
Hastings, Nebraska
GSK Investigational Site
Norfolk, Nebraska
GSK Investigational Site
Cincinnati, Ohio
GSK Investigational Site
Cleveland, Ohio
GSK Investigational Site
Tulsa, Oklahoma
GSK Investigational Site
Cranberry Township, Pennsylvania
GSK Investigational Site
Jefferson Hills, Pennsylvania
GSK Investigational Site
N. Huntingdon, Pennsylvania
GSK Investigational Site
Pittsburgh, Pennsylvania
GSK Investigational Site
Pittsburgh, Pennsylvania
GSK Investigational Site
Pittsburgh, Pennsylvania
GSK Investigational Site
Charleston, South Carolina
GSK Investigational Site
Greenville, South Carolina
GSK Investigational Site
Spartanburg, South Carolina
GSK Investigational Site
Brownsville, Texas
GSK Investigational Site
Dallas, Texas
GSK Investigational Site
Dickinson, Texas
GSK Investigational Site
Houston, Texas
GSK Investigational Site
Houston, Texas
GSK Investigational Site
Houston, Texas
Showing 40 of 52 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.